Affinity Investment Advisors LLC Has $551,000 Holdings in Horizon Pharma PLC (HZNP)

Affinity Investment Advisors LLC lessened its holdings in Horizon Pharma PLC (NASDAQ:HZNP) by 11.1% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 28,184 shares of the biopharmaceutical company’s stock after selling 3,524 shares during the quarter. Affinity Investment Advisors LLC’s holdings in Horizon Pharma were worth $551,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Sheets Smith Wealth Management purchased a new stake in Horizon Pharma in the 4th quarter worth $314,000. Bank of New York Mellon Corp increased its stake in Horizon Pharma by 2.6% in the 3rd quarter. Bank of New York Mellon Corp now owns 863,146 shares of the biopharmaceutical company’s stock worth $16,900,000 after buying an additional 21,982 shares in the last quarter. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp increased its stake in Horizon Pharma by 65.9% in the 3rd quarter. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp now owns 154,000 shares of the biopharmaceutical company’s stock worth $3,015,000 after buying an additional 61,200 shares in the last quarter. BlackRock Inc. increased its stake in Horizon Pharma by 1.3% in the 3rd quarter. BlackRock Inc. now owns 13,630,133 shares of the biopharmaceutical company’s stock worth $266,878,000 after buying an additional 178,887 shares in the last quarter. Finally, Vanguard Group Inc. increased its stake in Horizon Pharma by 3.8% in the 3rd quarter. Vanguard Group Inc. now owns 14,813,841 shares of the biopharmaceutical company’s stock worth $290,055,000 after buying an additional 547,099 shares in the last quarter. Institutional investors and hedge funds own 90.32% of the company’s stock.

Shares of Horizon Pharma stock opened at $23.04 on Tuesday. The stock has a market cap of $3.84 billion, a PE ratio of 19.53, a PEG ratio of 1.14 and a beta of 1.15. The company has a quick ratio of 1.86, a current ratio of 1.94 and a debt-to-equity ratio of 2.06. Horizon Pharma PLC has a twelve month low of $12.55 and a twelve month high of $24.03.

In related news, EVP Geoffrey M. Curtis sold 8,835 shares of the stock in a transaction dated Tuesday, February 5th. The shares were sold at an average price of $23.15, for a total value of $204,530.25. Following the completion of the transaction, the executive vice president now owns 32,202 shares of the company’s stock, valued at approximately $745,476.30. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Chairman Timothy P. Walbert sold 408,347 shares of the stock in a transaction dated Wednesday, November 14th. The shares were sold at an average price of $21.54, for a total transaction of $8,795,794.38. Following the completion of the transaction, the chairman now directly owns 650,404 shares of the company’s stock, valued at approximately $14,009,702.16. The disclosure for this sale can be found here. Company insiders own 3.90% of the company’s stock.

HZNP has been the subject of a number of research analyst reports. Stifel Nicolaus raised their price objective on Horizon Pharma from $25.00 to $35.00 and gave the company a “buy” rating in a research report on Thursday, November 1st. Cantor Fitzgerald restated a “buy” rating and set a $21.00 price objective on shares of Horizon Pharma in a research report on Thursday, October 18th. Mizuho restated a “buy” rating on shares of Horizon Pharma in a research report on Tuesday, October 16th. TheStreet upgraded Horizon Pharma from a “d+” rating to a “c” rating in a research report on Wednesday, October 31st. Finally, BidaskClub upgraded Horizon Pharma from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 5th. Five equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company’s stock. Horizon Pharma currently has a consensus rating of “Buy” and a consensus target price of $23.33.

WARNING: This news story was first reported by Community Financial News and is the property of of Community Financial News. If you are reading this news story on another site, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this news story can be viewed at https://www.com-unik.info/2019/02/12/affinity-investment-advisors-llc-has-551000-holdings-in-horizon-pharma-plc-hznp.html.

Horizon Pharma Company Profile

Horizon Pharma Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. The company's marketed medicine portfolio consists of RAVICTI for the treatment of urea cycle disorders; PROCYSBI to treat nephropathic cystinosis; ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; BUPHENYL to treat urea cycle disorders; and QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients.

Featured Article: Book Value Per Share – BVPS

Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Pharma PLC (NASDAQ:HZNP).

Institutional Ownership by Quarter for Horizon Pharma (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit